BackSummit Therapeutics Overview

Summit Therapeutics Current Cash

Summit Therapeutics's current cash is $420M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$419.37M
↑ 40.79% YoYΔ $121.49M vs prior year quarter

Peer trimmed avg / median

Loading

Summit Therapeutics Current Cash History

Loading

Summit Therapeutics vs. peers: Current Cash Comparison

Loading

Summit Therapeutics Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Summit Therapeutics (SMMT) FAQ

As of the most recent data (June 2026), SMMT shows a current cash of $420M. That compares with $300M in the prior-year period — up 40.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, SMMT's current cash is now $420M (was $300M) — a 40.8% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Summit Therapeutics is outperforming or lagging.

Tracking SMMT's current cash over time shows whether Summit Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $420M That compares with $300M in the prior-year period — up 40.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has Summit Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $420M) with ownership activity and broader fundamentals.